Previous studies have already shown higher gut microbial diversity and abundance of Ruminococcaceae and Agathobacter, indicating a higher progression-free survival rate in NSCLC patients treated with anti–PD-1/PD-L1 antibodies (260). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.